All In Biotech

Drug Trial Radar · NCT00542815

A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

A Phase III, Multicentre, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

632

Actual

Start

Nov 2007

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Oct 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a PIII multi-center, open-label, flexible dose, long-term safety study, that in conjunction with the E07(NCT00416520), E08(NCT00542386) and E09(NCT00451295) studies will allow exposure to MCI-196 for up to 52 weeks

Conditions

  • Chronic Kidney Disease
  • Dialysis
  • Hyperphosphatemia

Interventions

  • MCI-196Drug

    3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose

  • Another Phosphate binder (Sevelamer)Drug

    Current approved dosing recommendations for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change in Serum Phosphorus for MCI-196 and SevelamerTime frame: 52 weeks (Baseline-52 weeks)

Locations

115 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Graz, Austria

  • Site not named

    Frýdek-Místek, Czechia

  • Site not named

    Hradec Králové, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Tábor, Czechia

  • Site not named

    Ústí nad Labem, Czechia

  • Site not named

    Bordeaux, France

  • Site not named

    Montpelier, France

  • Site not named

    Paris, France

  • Site not named

    Aschaffenburg, Germany

  • Site not named

    Coesfeld, Germany

  • Site not named

    Darmstadt, Germany

  • Site not named

    Dortmund, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Homberg (Efze), Germany

  • Site not named

    Langen, Germany

  • Site not named

    Mannheim-Kafertal, Germany

  • Site not named

    Ajka, Hungary

  • Site not named

    Baja, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Esztergom, Hungary

  • Site not named

    Győr, Hungary

  • Site not named

    Hatvan, Hungary

  • Site not named

    Kisvárda, Hungary

  • Site not named

    Veszprém, Hungary

  • Site not named

    Ancona, Italy

  • Site not named

    Cernusco sul Naviglio, Italy

  • Site not named

    Como, Italy

  • Site not named

    Cremona, Italy

  • Site not named

    Lecco, Italy

  • Site not named

    Livorno, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Modena, Italy

  • Site not named

    Ostia Roma, Italy

  • Site not named

    Pavia, Italy

  • Site not named

    Perugia, Italy

  • Site not named

    Rome, Italy

  • Site not named

    Alor Star, Malaysia

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.